Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
Robert G. Gish, Man‐Fung Yuen, Henry Lik‐Yuen Chan, et al.
Antiviral Research (2015) Vol. 121, pp. 97-108
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

Therapeutic siRNA: state of the art
Bo Hu, Liping Zhong, Yuhua Weng, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1089
Recent progress in development of siRNA delivery vehicles for cancer therapy
Hyun Jin Kim, Ahram Kim, Kanjiro Miyata, et al.
Advanced Drug Delivery Reviews (2016) Vol. 104, pp. 61-77
Open Access | Times Cited: 387
Pharmacology of Antisense Drugs
C. Frank Bennett, Brenda F. Baker, Nguyen C. Pham, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 81-105
Closed Access | Times Cited: 378
Hepatitis B cure: From discovery to regulatory approval
Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, et al.
Journal of Hepatology (2017) Vol. 67, Iss. 4, pp. 847-861
Open Access | Times Cited: 316
Hepatitis B cure: From discovery to regulatory approval
Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, et al.
Hepatology (2017) Vol. 66, Iss. 4, pp. 1296-1313
Open Access | Times Cited: 269
Epidemiological and etiological variations in hepatocellular carcinoma
Evangelista Sagnelli, Margherita Macera, Antonio Russo, et al.
Infection (2019) Vol. 48, Iss. 1, pp. 7-17
Closed Access | Times Cited: 188
New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus
David Durantel, Fabien Zoulim
Journal of Hepatology (2016) Vol. 64, Iss. 1, pp. S117-S131
Closed Access | Times Cited: 183
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 2, pp. 276-331
Open Access | Times Cited: 81
<div>Lipid nanoparticles for targeted siRNA delivery &ndash; going from bench to bedside</div>
Victor Kotelianski, Timofei S. Zatsepin, Yuri Kotelevtsev
International Journal of Nanomedicine (2016) Vol. Volume 11, pp. 3077-3086
Open Access | Times Cited: 148
The Structural Biology of Hepatitis B Virus: Form and Function
Balasubramanian Venkatakrishnan, Adam Zlotnick
Annual Review of Virology (2016) Vol. 3, Iss. 1, pp. 429-451
Open Access | Times Cited: 137
Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection
Yuchen Xia, T. Jake Liang
Gastroenterology (2018) Vol. 156, Iss. 2, pp. 311-324
Open Access | Times Cited: 103
Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure
Tarik Asselah, Dimitri Loureiro, Nathalie Boyer, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 4, Iss. 11, pp. 883-892
Closed Access | Times Cited: 92
Exosome‐mediated small RNA delivery for gene therapy
Yu Zhou, Geyu Zhou, Chenfei Tian, et al.
Wiley Interdisciplinary Reviews - RNA (2016) Vol. 7, Iss. 6, pp. 758-771
Closed Access | Times Cited: 91
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
Isobel Okoye, Michael Houghton, D. Lorne Tyrrell, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 91
Hepatitis B virus reverse transcriptase – Target of current antiviral therapy and future drug development
Daniel N. Clark, Jianming Hu
Antiviral Research (2015) Vol. 123, pp. 132-137
Open Access | Times Cited: 78
Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers
Thomas Schluep, Jason D. Lickliter, James Hamilton, et al.
Clinical Pharmacology in Drug Development (2016) Vol. 6, Iss. 4, pp. 350-362
Open Access | Times Cited: 78
Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection
Yameng Pei, Chunting Wang, S. Frank Yan, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 15, pp. 6461-6479
Closed Access | Times Cited: 77
Towards HBV curative therapies
Raymond F. Schinazi, Maryam Ehteshami, Leda Bassit, et al.
Liver International (2018) Vol. 38, Iss. S1, pp. 102-114
Open Access | Times Cited: 76
Novel targets for hepatitis B virus therapy
Barbara Testoni, David Durantel, Fabien Zoulim
Liver International (2017) Vol. 37, Iss. S1, pp. 33-39
Open Access | Times Cited: 74
Updates on Chronic HBV: Current Challenges and Future Goals
Hannah M. Lee, Bubu A. Banini
Current Treatment Options in Gastroenterology (2019) Vol. 17, Iss. 2, pp. 271-291
Closed Access | Times Cited: 65
Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates
Santiago Grijalvo, Adele Alagia, Andreia F. Jorge, et al.
Genes (2018) Vol. 9, Iss. 2, pp. 74-74
Open Access | Times Cited: 63
The Role of Hepatitis B Core-Related Antigen
Takako Inoue, Yasuhito Tanaka
Genes (2019) Vol. 10, Iss. 5, pp. 357-357
Open Access | Times Cited: 62
Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination
Claudia J. Dembek, Ulrike Protzer, Michael Roggendorf
Current Opinion in Virology (2018) Vol. 30, pp. 58-67
Closed Access | Times Cited: 59
Small interfering RNA from the lab discovery to patients' recovery
Marie Caillaud, Mévidette El Madani, Liliane Massaad-Massade
Journal of Controlled Release (2020) Vol. 321, pp. 616-628
Open Access | Times Cited: 55
Longterm Outcome of Therapeutic Vaccination with a Third Generation Pre-S/S HBV Vaccine (PreHevbrioR) of Chronically HBV Infected Patients
Hedwig Roggendorf, Daniel Shouval, Michael Roggendorf, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 4, pp. 364-364
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top